In breast cancer treatment assessment of receptor status (estrogen (ER), progesterone (PR) and Her2-neu receptor (HER2)) by immunohistochemistry (IHC) from breast biopsy is used for tumor subtype classification. This evidence concerns the gene PGR and breast carcinoma.